---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-004263"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T12:00:56.160738+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics extends Series A conversion price adjustment indefinitely; discloses 2023 budget of ~$21.7M

## Summary
- Conversion price (lower of closing price or 5-day avg) for Series A Preferred now indefinite per amendment with 3i, LP.
- Proposed 2023 budget: $4.9M milestone payments, $10.5M development costs, $6.3M G&A; total ~$21.7M.
- Company intends to finance budget through capital raising; no assurance of sufficient capital.
- Series A Preferred issued in May 2021; 3i also holds a secured promissory note from November 2022.

## SEC filing metadata
- accession: 0001213900-23-004263
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.03, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023004263/0001213900-23-004263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023004263/ea172038-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-004263
- JSON: https://secwatch.observer/filing/0001213900-23-004263.json
- Plain text: https://secwatch.observer/filing/0001213900-23-004263.txt

## Key facts
- Material Agreements
  Allarity Therapeutics, Inc. amended Letter Agreement with 3i, LP valued at Amendment to extend conversion price modification until terminated by Company and 3i (effective 2023-01-23).
  - Action: amendment
  - Counterparty: 3i, LP
  - Value: Amendment to extend conversion price modification until terminated by Company and 3i
  - Effective: 2023-01-23
  source text: On January 23, 2023, the Company and 3i amended the Letter Agreement to provide the term Conversion Price will be in effect until terminated by the Company and 3i.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023004263/0001213900-23-004263-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.